ObsEva SA (OBSV) Has Broken Out To A New High On Study Results
Markets2018-06-18
0 Views
ObsEva SA (OBSV) announced Monday morning that its Phase 2b trial of linzagolix, for the treatment of endometriosis-associated pain, met its primary and secondary endpoints.
Source: RTTNews
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
Experience 5-Star Car Hire in Switzerland with Local Chauffeurs
Understanding The Importance Of Financial Habits
